Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti-angiogenic properties

Biochemical and Biophysical Research Communications

Volumn 354, Issue 2, 2007, Pages 434-439

  Karagiannis, Emmanouil D ^a   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Endogenous; Endothelial cell; Hexastatin; Inhibitor; Pentastatin; Tetrastatin

Indexed keywords

GELATINASE A; HEXASTATIN; PENTASTATIN; PEPTIDE; TETRASTATIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846492441     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.231     Document Type: Article

References (19)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
3. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
4. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell. Biol. 33 (2001) 357-369
5. Timpl R. Macromolecular organization of basement membranes. Curr. Opin. Cell. Biol. 8 (1996) 618-624
6. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., Ericksen M.B., Dhanabal M., Simons M., Post M., Kufe D.W., Weichselbaum R.R., Sukhatme V.P., and Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60 (2000) 2520-2526
7. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., Cosgrove D., and Kalluri R. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J. Clin. Invest. 115 (2005) 2801-2810
8. Petitclerc E., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras Jr. M.P., Hudson B.G., and Brooks P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275 (2000) 8051-8061
9. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J.W., Sukhatme V.P., and Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275 (2000) 1209-1215
10. Maeshima Y., Colorado P.C., Torre A., Holthaus K.A., Grunkemeyer J.A., Ericksen M.B., Hopfer H., Xiao Y., Stillman I.E., and Kalluri R. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275 (2000) 21340-21348
11. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., Kharbanda S., and Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276 (2001) 15240-15248
12. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 100 (2003) 4766-4771
13. Ishiyama M., Tominaga H., Shiga M., Sasamoto K., Ohkura Y., and Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull. 19 (1996) 1518-1520
14. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
15. Clamp M., Cuff J., Searle S.M., and Barton G.J. The Jalview Java alignment editor. Bioinformatics 20 (2004) 426-427
16. Romesburg H.C. Cluster Analysis for Researchers (1984), Lifetime Learning Publications, Belmont, Calif
17. Farinelle S., Malonne H., Chaboteaux C., Decaestecker C., Dedecker R., Gras T., Darro F., Fontaine J., Atassi G., and Kiss R. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J. Pharmacol. Toxicol. Methods 43 (2000) 15-24
18. Addison C.L., Nor J.E., Zhao H., Linn S.A., Polverini P.J., and Delaney C.E. The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent. BMC Cell Biol. 6 (2005) 38
19. McLachlan G.J. Cluster analysis and related techniques in medical research. Stat. Methods Med. Res. 1 (1992) 27-48